Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Ribo Life Science Co., Ltd.
蘇州瑞博生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

APPOINTMENT OF CHIEF MEDICAL OFFICER AND CHIEF BUSINESS OFFICER

The board (the "**Board**") of directors (the "**Directors**") of Suzhou Ribo Life Science Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that, with effect from March 25, 2026, (1) Dr. Anders Gabrielsen has been appointed as the chief medical officer ("**CMO**") of the Company, who will be responsible for the overall clinical development, medical affairs and regulatory compliance of our Company; (2) Dr. John Taylor has been appointed as the chief business officer of the Company, who will be responsible for the overall business development, in-licensing and out-licensing collaborations and strategic investments of our Company; and (3) Dr. Gan Liming no longer serves as CMO and will continue to serve as an executive Director, co-chief executive officer and global R&D president of the Company.

Dr. Anders Gabrielsen, aged 59, joined our Group in 2023 and has served as vice president and head of global clinical development. Dr. Gabrielsen is a seasoned physician-scientist with over 20 years of experience in cardiovascular, renal, and metabolic therapeutics. Dr. Gabrielsen obtained his M.D. from the University of Copenhagen in Denmark in 1994, completed clinical rotations, clinical cardiovascular research, and a visiting Marie Curie postdoctoral research fellowship in myocardial gene expression at the Karolinska Institute, and was subsequently awarded a Doctor of Medical Sciences (DMSc) in 2003 at the University of Copenhagen. From 2003 to 2011, he trained and practiced as a cardiologist and internist at the Karolinska Institute and Karolinska University Hospital in Sweden, specializing in heart failure. Prior to joining our Company, from 2011 to 2023, Dr. Gabrielsen served as a physician-scientist in clinical development and medical affairs at leading multinational corporations including Bayer AG, Novartis AG, and AstraZeneca PLC, where he played key lead and executive roles in core clinical and medical teams covering all aspects of cardiology and internal medicine, with a focus on translational and clinical cardiovascular science and medical implementation.

Dr. John Taylor, aged 56, joined our Group in 2023 and has served as vice president and head of global business development. With over 20 years of experience in the global biopharmaceutical industry, Dr. Taylor brings deep expertise spanning from foundational scientific research to corporate business development. Dr. Taylor obtained his Ph.D. in Biochemistry from the University of Bristol in the United Kingdom in 1991, with a focus on DNA-protein recognition. From 1991 to 1993, he subsequently conducted research on DNA mismatch repair at Duke University in the United States. From 1993 to 2003, Dr. Taylor served at global research and development in Pfizer Inc., responsible for innovative R&D and leading projects. From 2004 to 2023, Dr. Taylor held various positions at AstraZeneca PLC, including head of biology, respiratory and inflammation from 2004 to 2011, and leadership roles in search and evaluation and transaction execution in business development from 2011 to 2023.

The Board would like to take this opportunity to express its warmest welcome to Dr. Anders Gabrielsen and Dr. John Taylor on their new appointments with the Group.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, March 25, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.